AstraZeneca's Q3 revenue up 50% to $9.8 billion

Friday, 12. November 2021 08:05

AstraZeneca plc unveiled on Friday that its revenue for the third quarter of the fiscal year increased 50% when compared to the same period last year to $9.86 billion.

Meanwhile, total revenue excluding the coronavirus vaccine rose 34% year-over-year climbing to $8.82 billion. The company noted that it had a reported loss per share of $1.10 in this trimester, while its core earnings per share saw a yearly gain of 14% to stand at $1.08.

AstraZeneca CEO Pascal Soriot commented on the report: "Our broad portfolio of medicines and diversified geographic exposure provides a robust platform for long-term sustainable growth. Following accelerated investment in upcoming launches after positive data flow, we expect a solid finish to the year and our earnings guidance is unchanged."

Related Links: AstraZeneca plc
Author:
Baha Breaking the News (BBN) / OL